bgb-43395 alone or as part of combination therapies in participants with breast cancer and other advanced solid tumors

Conditions: Advanced Solid Tumor; Advanced Breast Cancer; Metastatic Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma; Hormone Receptor Positive Malignant Neoplasm of Breast; HER2-negative Breast Cancer; Hormone Receptor Positive HER-2 Negative Breast Cancer; Non-small Cell Lung Cancer

Summary: this is a dose escalation and dose expansion study to compare how well bgb-43395, a selective cyclin-dependent kinase 4 (cdk4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants with hormone receptor positive (hr+) and human epidermal growth factor 2 negative (her2-) breast cancer (bc) and other advanced solid tumors. the main purpose of this study is to explore the recommended dosing for bgb-43395.


Eligibility criteria:
inclusion criteria: * phase 1a (dose escalation) and 1b (dose expansion): participants with histologically or cytologically confirmed advanced, metastatic, or unresectable solid tumors associated with dependency on cdk4, including hr+ breast cancer, ovarian cancer, endometrial cancer, non-small cell lung cancer, and others. * phase 1a: received prior therapy for their condition (if available) and should be refractory to, or intolerant of standard-of-care therapies. in regions where approved and available, participants with hr+ breast cancer must have received at least 2 prior lines of treatment including endocrine therapy and a cdk4/6 inhibitor. for combination with elacestrant, participants must have received at least 1 prior line of treatment for advanced/metastatic disease including prior endocrine therapy and cdk4/6 inhibitor in either the adjuvant or advanced/metastatic setting. * phase 1b: selected tumor cohorts will include hr+/her2- breast cancer and additional tumor types. * phase 1b: participants with hr+/her2- breast cancer enrolled in regions where cdk4/6 inhibitors are approved and available must have received at least one line of therapy for advanced disease including endocrine therapy and a cdk4/6 inhibitor. participants can have received up to 2 lines of prior cytotoxic chemotherapy for advanced disease. * stable eastern cooperative oncology group (ecog) performance status ≤ 1. * female participants with metastatic hr+/her2- breast cancer must be postmenopausal or receiving ovarian function suppression treatment. * adequate organ function without symptomatic visceral disease. exclusion criteria: * prior therapy selectively targeting cdk4 (prior cdk4/6 inhibitor therapy is permitted and required in local regions where it is approved and available). * known leptomeningeal disease or uncontrolled, untreated brain metastases. * any malignancy ≤ 3 years before the first dose of study treatment(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast). * uncontrolled diabetes. * infection requiring systemic antibacterial, antifungal, or antiviral therapy ≤ 28 days before the first dose of study drug(s), or symptomatic covid-19 infection. * participants with untreated chronic hepatitis b or chronic hepatitis b virus (hbv) carriers with hbv dna ≥ 500 iu/ml (or ≥ 2500 copies/ml) at screening. * participants with active hepatitis c infection. * prior allogeneic stem cell transplantation, or organ transplantation. note: other protocol defined inclusion/exclusion criteria may apply.

Keywords: breast cancer advanced solid tumor advanced breast cancer hormone receptor positive breast cancer her2-negative breast cancer hormone receptor positive her-2 negative breast cancer bgb-43395 non-small cell lung cancer